Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,764

Stocks News & Analysis

stocks

Solving the Australian equities conundrum

Where to look in a heavily concentrated index.
stocks

Cutting our fair value on ASX share after poor guidance

Our view after the shares stand after a 20% drop.
stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,868.2033.10-0.37%
CAC 408,022.6929.82-0.37%
DAX 4024,130.1432.51-0.13%
Dow JONES (US)47,792.67232.380.49%
FTSE 1009,655.5313.520.14%
HKSE25,540.78106.550.42%
NASDAQ23,531.7544.74-0.19%
Nikkei 22550,602.8052.30-0.10%
NZX 50 Index13,371.0683.72-0.62%
S&P 5006,846.686.170.09%
S&P/ASX 2008,579.4031.70-0.37%
SSE Composite Index3,900.509.03-0.23%

Market Movers